Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 3

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Hepatocellular 3Liver Neoplasms 2Liver Neoplasms, Experimental 1Adenoma, Liver Cell 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × carotuximab × Gastrointestinal × Clear all
NCT02560779 2020-07-17

Trial of TRC105 and Sorafenib in Patients With HCC

Tracon Pharmaceuticals Inc.

Phase 1/2 Completed
27 enrolled 11 charts
Gastrointestinal

Carcinoma, Hepatocellular

NCT01306058 2019-01-23

Sorafenib and TRC105 in Hepatocellular Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
27 enrolled 32 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Liver Neoplasms, Experimental, Adenoma, Liver Cell

NCT01375569 2017-07-28

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡